HT 61

Drug Profile

HT 61

Alternative Names: HT-61; HY 50A

Latest Information Update: 10 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Helperby Therapeutics
  • Class Antibacterials; Quinolones; Small molecules
  • Mechanism of Action Cell membrane modulators; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Staphylococcal infections

Most Recent Events

  • 10 Jun 2015 Phase III development is ongoing in the United Kingdom
  • 04 Dec 2013 Phase-III development is ongoing in UK
  • 21 Feb 2012 Helperby Therapeutics initiates enrolment in a phase II trial for Staphylococcal infections in United Kingdom (EudraCT2011-002438-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top